Efficacy Of Zercepac^? Compared With Herceptin^? Combined With Pertuzumab In Neoadjuvant Therapy For HER2 Positive Breast Cancer

Objectives:Analyze the efficacy and safety that Zercepac~?combined with pertuzumab in neoadjuvant therapy of HER2-positive breast cancer,and to compare with Herceptin~?combined with pertuzumab.Methods:Medical records of patients with HER2-positive early breast cancer who received neoadjuvant therapy with Zercepac~?or Herceptin~?combined with pertuzumab and chemotherapy,then surgery in Breast Cancer Treatment Center of Yunnan Cancer Hospital from October 2021 to August 2022 were retrospectively collected.In the end,48 patients received Zercepac~?and pertuzumab,87 patients received Herceptin~?and pertuzumab.The efficacy and safety of neoadjuvant therapy were compared between the two groups of patients who received Zercepac~?or Herceptin~?combined with pertuzumab and chemotherapy by SPSS 26.0 statistical software,and factors affecting the rate of pathologic complete response(p CR)were analyzed.The primary endpoint was p CR,and the secondary endpoint was Overall Response Rate(ORR)and adverse effects.Results:In the 48 patients treated with Zercepac~?and pertuzumab,45(95.83%)patients were invasive ductal carcinoma,1(2.08%)patients was invasive lobular carcinoma,and 2(4.17%)patients were ductal carcinoma in situ.In the 87 patients treated with Herceptin~?and pertuzumab,86(98.85%)patients were invasive ductal carcinoma,1(1.15%)patient was invasive lobular carcinoma.There was no significant difference in p CR rate between Zercepac~?(33/48,68.75%)and Herceptin~?(62/87,71.26%)after neoadjuvant treatment(P=0.76).ORR(Zercepac~?,95.83%;Herceptin~?,97.70%;P=0.62)had no significant difference,and the incidence of Adverse Event was similar.Conclusions:1.The efficacy of Zercepac~?was consistent with that of Herceptin~?combined with Pertuzumab in neoadjuvant therapy for HER2-positive breast cancer.2.The safety of Zercepac~?was consistent with that of Herceptin~?combined with Pertuzumab in neoadjuvant therapy for HER2-positive breast cancer.3.As a biosimilar of trastuzumab,Zercepac~?is safe and effective when combined with pertuzumab,which supports the clinical application of Zercepac~?combined with pertuzumab in neoadjuvant therapy for HER2-positive breast cancer.